Airway Therapeutics LLC, founded with a mission to develop innovative protein therapies, focuses on protecting against lung disorders, particularly in vulnerable populations like preterm infants. The company is dedicated to advancing the treatment of bronchopulmonary dysplasia (BPD) through its lead product, Zelpultide Alfa (AT-100), which aims to address unmet medical needs in neonatal care. Airway Therapeutics leverages cutting-edge biotechnology to create solutions that improve respiratory health and outcomes.

Notable figures affiliated with Airway Therapeutics include Raquel Arroyo, PhD, PharmD, who has been recognized for her contributions to neonatal lung research. The company has achieved significant milestones, including the initiation of international clinical trials and dosing the first patients in Phase 1b studies. These achievements underscore Airway Therapeutics' impact on advancing medical research and potential treatments for lung disorders, positioning it as a key player in the biotechnology sector focused on respiratory health.